Oh Yun Jung, An Jung Nam, Kim Clara Tammy, Yang Seung Hee, Lee Hajeong, Kim Dong Ki, Joo Kwon Wook, Paik Jin Ho, Kang Shin-Wook, Park Jung Tak, Lim Chun Soo, Kim Yon Su, Lee Jung Pyo
Department of Internal Medicine, Cheju Halla General Hospital, Jeju, Korea.
Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
PLoS One. 2015 Jul 15;10(7):e0132826. doi: 10.1371/journal.pone.0132826. eCollection 2015.
The circulating tumor necrosis factor receptors (TNFRs) could predict the long-term renal outcome in diabetes, but the role of circulating TNFRs in other chronic kidney disease has not been reported. Here, we investigated the correlation between circulating TNFRs and renal histologic findings on kidney biopsy in IgA nephropathy (IgAN) and assessed the notion that the circulating TNFRs could predict the clinical outcome. 347 consecutive biopsy-proven IgAN patients between 2006 and 2012 were prospectively enrolled. Concentrations of circulating TNFRs were measured using serum samples stored at the time of biopsy. The primary clinical endpoint was the decline of estimated glomerular filtration rate (eGFR; ≥ 30% decline compared to baseline). Mean eGFR decreased and proteinuria worsened proportionally as circulating TNFR1 and TNFR2 increased (P < 0.001). Tubulointerstitial lesions such as interstitial fibrosis and tubular atrophy were significantly more severe as concentrations of circulating TNFRs increased, regardless of eGFR levels. The risks of reaching the primary endpoint were significantly higher in the highest quartile of TNFRs compared with other quartiles by the Cox proportional hazards model (TNFR1; hazard ratio 7.48, P < 0.001, TNFR2; hazard ratio 2.51, P = 0.021). In stratified analysis according to initial renal function classified by the eGFR levels of 60 mL/min/1.73 m2, TNFR1 and TNFR2 were significant predictors of renal progression in both subgroups. In conclusion, circulating TNFRs reflect the histology and clinical severity of IgAN. Moreover, elevated concentrations of circulating TNFRs at baseline are early biomarkers for subsequent renal progression in IgAN patients.
循环肿瘤坏死因子受体(TNFRs)可预测糖尿病患者的长期肾脏预后,但循环TNFRs在其他慢性肾脏病中的作用尚未见报道。在此,我们研究了IgA肾病(IgAN)患者循环TNFRs与肾活检组织学结果之间的相关性,并评估了循环TNFRs能否预测临床结局。前瞻性纳入了2006年至2012年间347例经活检证实的连续性IgAN患者。使用活检时储存的血清样本测定循环TNFRs的浓度。主要临床终点是估计肾小球滤过率(eGFR)下降(与基线相比下降≥30%)。随着循环TNFR1和TNFR2水平升高,平均eGFR下降,蛋白尿呈比例恶化(P<0.001)。无论eGFR水平如何,随着循环TNFRs浓度升高,肾小管间质病变如间质纤维化和肾小管萎缩明显更严重。根据Cox比例风险模型,与其他四分位数相比,TNFRs最高四分位数患者达到主要终点的风险显著更高(TNFR1;风险比7.48,P<0.001,TNFR2;风险比2.51,P=0.021)。在根据eGFR水平60 mL/min/1.73 m2分类的初始肾功能进行的分层分析中,TNFR1和TNFR2在两个亚组中均是肾脏进展的显著预测因素。总之,循环TNFRs反映了IgAN的组织学和临床严重程度。此外,基线时循环TNFRs浓度升高是IgAN患者随后肾脏进展的早期生物标志物。